

Pancreatic Cancer: Advances in Science and Clinical Care

September 21 - 24, 2018 | Boston, MA

AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A001. A phase II trial of neoadjuvant FOLFIRINOX in combination with losartan followed by chemoradiotherapy in locally advanced pancreatic cancer: R0 resection rate and clinical outcomes. Jennifer Wo, Massachusetts General Hospital, Boston, MA, USA.

A002. Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Harri Jarvelainen, DrugCendR Inc, La Jolla, CA, USA.

A003, PR05. RNA profiling and the impact of current classifiers on survival in patients receiving combination chemotherapy on the COMPASS trial. Grainne O'Kane, Princess Margaret Cancer Centre, Toronto, On, Canada.

A004. KrasG12D activates Nix-mediated Mitophagy to promote Pancreatic Cancer. Brinda Alagesan, Cold Spring Harbor Laboratory Cancer Ctr., Cold Spring Harbor, NY, USA.

A005. Acinar cell expansion: an early step in pancreatic tumorigenesis. Patrick Neuhoefer, Stanford University, Stanford, CA, USA.

A006. Common bacterial strains exist between tissue and oral samples in pancreatic cancer subjects. Naisi Zhao, Department of Public Health & Community Medicine, Tufts University School of Medicine, Tufts University, Boston, MA, USA.

A007. Developing Novel Antibodies against Cell surface-accessible Epitopes in Pancreatic Cancer. Tobiloba Oni, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

A008. Development of a novel biomarker panel to detect pancreatic ductal adenocarcinoma circulating tumor cells. Moen Sen, Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

A009. Early genetic changes in pancreatic cancer cells lead to altered exosome content. Rachel Dittmar, MD Anderson Cancer Center, Houston, TX, USA.

A010. Improving pancreatic cancer risk prediction models using circulating metabolites. Ana Babic, Dana-Farber Cancer Institute, Boston, MA, USA.

A011. Pancreatic cancer screening and risk stratification using apolipoprotein A2-isoforms. Kazufumi Honda, National Cancer Center, Tokyo, Japan.

A012. A comparative proteomic analysis using quantitative LC-MS/MS profiling of human pancreatic adenocarcinoma, adjacent-normal tissue, and patient-derived tumour xenografts in mice. Orla Coleman, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.



Pancreatic Cancer: Advances in Science and Clinical Care

September 21 - 24, 2018 | Boston, MA

AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A013. A genome-wide screen for functional inherited high-frequency genetic variants that affect survival in resectable pancreatic ductal adenocarcinoma. Lukasz Grochola, University of Zurich / Cantonal Hospital Winterthur, Zurich / Winterthur, Zurich, Switzerland.

A014. About the good use of the pancreatic cancer TCGA data : importance of curation and proposal of web-based tool. JEROME CROS, INSERM U1149, Beaujon Hospital, Clichy, France.

A015. Applications of in vivo functional genomics: Leveraging surfaceome-derived functional networks for oncogene discovery and biomarker characterization in pancreatic cancer. Johnathon Rose, UT MD Anderson Cancer Center, Houston, TX, USA.

A016. Comparison of Primary and Metastatic Pancreatic Cancer by Integration of Clinical, Pathologic, Genomic and Transcriptional Features. Ashton Connor, University of Toronto, Toronto, Ontario, Canada.

A017. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Luis Arnes, Columbia University, New York, NY, US.

A018. Comprehensive genome-scale DNA methylation analysis of early PDAC development. Brian Mears, Center for Epigenetics, Johns Hopkins University, Baltimore, MD, USA.

A019. Development of an experimental system for the estimation of epistasis in pancreatic cancer driver mutations. Jungeui Hong, Memorial Sloan Kettering, New York, NY, USA.

A020. Elucidating the role of p53 in the cellular origins of pancreatic cancer development. Brittany Flowers, Stanford University School of Medicine, Stanford, CA, USA.

A021. Engrailed-1 promotes survival of metastatic pancreatic cancer cells via regulation of COMPASS pathway. Chang-il Hwang, University of California, Davis, Davis, CA, USA.

A022. Epigenetic landscapes of pancreatic ductal adenocarcinoma. Yuna Blum, French League Against Cancer, Paris, France.

A023. Exploring the role of Arid1a in acinar cell homeostasis/regeneration and epithelial-mesenchymal transition in the pancreas. Wenjia Wang, University of Rochester Medical Center, Rochester, NY, USA.

A024. Hallmarks of Homologous Repair Deficient Pancreatic Ductal Adenocarcinoma. Robert Denroche, PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.



Pancreatic Cancer: Advances in Science and Clinical Care

September 21 - 24, 2018 | Boston, MA

AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A025. Individual tumor genetic histories converge to produce molecular subtypes of pancreatic cancer. Faiyaz Notta, Princess Margaret Cancer Centre, Toronto, ON, Canada.

A026. Knock-down of FOXN2 in PANC-1 cells causes deficiencies in proliferation and migration. Elizabeth Maurais, University of New Hampshire - Manchester, Manchester, NH, USA.

A027. Loss of p53 tumor suppression function is required for pancreatic cancer progression. Claudia Tonelli, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

A028. Next-generation sequencing defines striking genetic heterogeneity in intraductal papillary mucinous neoplasms of the pancreas. Catherine Fischer, The Johns Hopkins University, Baltimore, MD, USA.

A029. Not all KRAS mutations in pancreatic ductal adenocarcinoma are created equal: Associations with clinicopathological characteristics and patterns of disease recurrence. Vicente Morales-Oyarvide, Dana-Farber Cancer Institute, Boston, MA, USA.

A030. Pancreatic cancer risk in offspring when both parents have cancer. Gloria Petersen, Mayo Clinic, Rochester, MN, USA.

A031. Real-world implementation of universal genetic counseling and multigene germline testing in individuals with pancreatic cancer. Matthew Yurgelun, Dana-Farber Cancer Institute, Boston, MA, USA.

A032. Reducing protein stability underlies the protumoral function of L16R(47T>G) CDKN2A, a mutation associated with familial pancreatic cancer. David Marks, Mayo Clinic, Rochester, MN, USA.

A033. Role of alternative polyadenylation events in pancreatic ductal adenocarcinoma. Swati Venkat, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A034. Target X is a super-enhancer tagged human cancer gene and a novel therapeutic target in pancreatic cancer controlling cell migration and proliferation. Divya Sood, Moores Cancer Center, Department of Surgery, University of California San Diego, La Jolla, CA, USA.

A035. The transcriptional landscape of protein-coding and long noncoding RNAs in pancreatic adenocarcinoma revealed by total RNAseq analysis of matched tumor and nontumor patient samples. Eduardo Reis, University of Sao Paulo, Sao Paulo, SP, Brazil.



Pancreatic Cancer: Advances in Science and Clinical Care

September 21 - 24, 2018 | Boston, MA

AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A036. Transcriptional and Spatial Heterogeneity of Squamous Features in Pancreatic Ductal Adenocarcinoma. Akimasa Hayashi, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A037. Uncovering the TCF12 transcriptional network promoting pancreatic cancer metastasis. Karen Mann, Moffitt Cancer Center, Tampa, FL, USA.

A038. Using pancreatic cancer organoids to study genome catastrophes. Whitney Johnson, Dana-Farber Cancer Institute, Boston, MA, USA.

A039. Ethnic disparities in the mortality rates following pancreatic cancer diagnosis: A population-based study. Mohamed Gad, Cleveland Clinic Foundation, Cleveland, OH, USA.

A040. Collagen Targeted MRI Accurately Measures the Fibrotic Response to FOLFIRINOX Treatment in a Murine Model of Pancreatic Cancer. Derek Erstad, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

A041. Drug-loaded microparticles reduce gemcitabine resistance in pancreatic cancer. Maria Munoz-Sagastibelza, SUNY Downstate Medical Center, Brooklyn, NY, USA.

A042. RESPECT - A multicenter retrospective study on preoperative chemotherapy with FOLFIRINOX in locally advanced and borderline respectable pancreatic cancer. Maximilian Weniger, Department of General, Visceral, and Transplantation Surgery, Ludwig Maximilians University, Munich, Germany.

A043. Acquisition of a squamous cell identity promotes pancreatic ductal adenocarcinoma progression. Tim Somerville, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

A044. Chronic ethanol exposure of human pancreatic normal ductal epithelial cells induces cancer stem cell phenotype through SATB2. Rakesh Srivastava, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

A045. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subgroup of pancreatic cancer. Shouhui Yang, National Cancer Institute, Bethesda, MD, USA.

A046. Evaluation of the Transcriptional Repressor REST during pancreas injury and acinar trans-differentiation. Julie Bray, University of Florida, Gainesville, FL, USA.

A047. GLI1/GLI2 functional interplay is required for GLI2-induced pancreatic cancer initiation. Ezequiel Tolosa, Mayo Clinic, Rochester, MN, USA.



Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A048. MicroRNA-431 promotes metastasis of pancreatic neuroendocrine tumor by silencing RasGAP tumor suppressor, DAB2IP. Yi-Chieh Nancy Du, Weill Cornell Medicine, New York, NY, US.

A049. Mutated KRAS knocked-out by CRISPR/Cas9. Eva Pilarsky, Department of Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, Germany.

A050. Oncogenic mechanism of soluble Keratin 17 offers potential therapeutic vulnerability in pancreatic cancer. Ryan Kawalerski, Stony Brook University, Stony Brook, NY, USA.

A051. Polo-like kinase 3 is essential in inducing anoikis and suppressing metastasis in pancreatic ductal adenocarcinoma. Jie Fu, UT MD Anderson Cancer Center, Houston, TX, USA.

A052. PRDX3/FOXM1 axis is associated with pancreatic adenocarcinoma aggressiveness and can be targeted by a novel therapeutic strategy. JEROME RAFFENNE, INSERM U1149, BEAUJON HOSPITAL, CLICHY, FRANCE.

A053. Syndecan-1 is a novel regulator for macropinocytosis in pancreatic cancer. Wantong Yao, MD Anderson Cancer Center, University of TX, Houston, TX, US.

A054. The BRG1/SOX9 axis plays a critical role for acinar cell–derived pancreatic tumorigenesis. Motoyuki Tsuda, Gastroenterology and Hepatology, Kyoto University, Kyoto, Japan.

A055. The ETS transcription factor Spdef interacts with c-Myc and promotes pancreatic cancer. Georgi Yordanov, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

A056. The oncogenic context modulates the function of NFκB2 Signaling in the Carcinogenesis in the Pancreas. Zonera Hassan, Medical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

A057. The role of chemokine CXCL16 in pancreatic carcinogenesis. Yojiro Sakuma, The Japan Baptist Hospital, Kyoto, Japan.

A058. TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth. Sam Grimaldo, University of Illinois, Chicago, Chicago, IL, USA.

A059. Trefoil factor 1 inhibits epithelial-mesenchymal transition (EMT) of pancreatic intraepithelial neoplasm. Junpei Yamaguchi, Nagoya University, Nagoya, Aichi, Japan.

A060. USP21 promotes stemness of pancreatic cancer cells and bypass of KRAS extinction. Pingping Hou, UT MD Anderson Cancer Center, Houston, TX, USA.



Pancreatic Cancer: Advances in Science and Clinical Care

September 21 - 24, 2018 | Boston, MA

AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A061. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. BO TU, MD Anderson Cancer Center, Housotn, TX, USA.

A062. 2-Hydroxypropyl-beta-cyclodextrin encapsulated α-bisabolol (CD-BSB) improves the antitumor effect of α-bisabolol for pancreatic cancer. Taisuke Baba, Division of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

A063. A multiscale map of the stem cell state in pancreatic adenocarcinoma. Nikki Lytle, University of California, San Diego, La Jolla, CA, USA.

A064. Activin secretion from stromal cells promotes pancreatic cancer metastasis. Georgina Mancinelli, University of Illinois Chicago, Chicago, IL, USA.

A065. Cellular origin affects the phenotype of pancreatic ductal adenocarcinoma cells. Janel Kopp, University of British Columbia, Vancouver, BC, Canada.

A066. Combining the BET inhibitor JQ1 with the PARP inhibitor olaparib as a potential treatment for pancreatic ductal adenocarcinoma. Aubrey Miller, University of Alabama at Birmingham, Birmingham, AL, US.

A067. Defining the role of chromatin remodeling complexes in pancreatic cancer stem cells. Lesley Ferguson, University of California San Diego, La Jolla, CA, USA.

A068. From RNA molecular subtyping to immunohistochemistry and in vivo validation: Keratin 17 identifies and drives pancreatic cancer aggression. Lucia Roa-Peña, Department of Pathology, Stony Brook University, Stony Brook, NY, US.

A069. Global regulation of H3K36me2 underlies perturbations in epithelial plasticity. Salina Yuan, University of Pennsylvania, Philadelphia, PA, USA.

A070. GSTP1 knockdown and inhibition impairs pancreatic ductal adenocarcinoma (PDAC) growth. Rahul Raj Singh, Department of Biological Sciences, North Dakota State University, Fargo, ND, USA.

A071. Impact of neuroendocrine tumor classification on pancreas cancer survival rates in the USA, 1995-2014. Margaret Mandelson, Virginia Mason, Seattle, WA, USA.

A072. Inhibition of geranylgeranyl diphosphate synthase as a novel therapeutic strategy for pancreatic adenocarcinoma. Staci Haney, University of Nebraska Medical Center, Omaha, NE, USA.

A073. Intraductal Epithelial Neoplasia Model of Human Pancreatic Cancer. Koji Miyabayashi, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.



Pancreatic Cancer: Advances in Science and Clinical Care

September 21 - 24, 2018 | Boston, MA

AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A074. Metabolic rewiring and chemoresistance mechanisms of the most aggressive molecular subtype of pancreatic cancer. Chun-Hao Pan, Department of Pathology, Stony Brook Medicine, Stony Brook, NY, US.

A075. Modeling pancreatic ductal adenocarcinoma using normal human acinar and ductal cells. Jun Liu, The University of TX Health San Antonio, San Antonio, TX, USA.

A076. Modulation of oncogenic microRNAs by bitter melon in human pancreatic cancer. Dominique Reed, Univ. of Colorado Denver-AMC, Aurora, CO, USA.

A077. Pancreatic cancer recurrence patterns and evaluation of a novel radiomics-based method for liver metastasis risk assessment. Constantinos Zambirinis, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A078. Single cell transcriptomic profiling identifies a dormancy signature in novel mouse model of pancreatic cancer dormancy. Darren Carpizo, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

A079. SuperCT, a supervised machine learning method to characterize cell types and states within solid tumor tissues. Wei Lin, Translational Genomics Institute, Phoenix, AZ, USA.

A080. Targeting c-MET signaling overcomes Triptolide resistance in pancreatic cancer. Shweta Sharma, UCSD, San Diego, CA, USA.

A081. The novel agent phospho-valproic acid enhances the efficacy of chemotherapeutic agents for inhibiting pancreatic cancer growth. Matthew DiGiovanni, Stony Brook Medicine, Stony Brook, NY, USA of America.

A082. Therapeutic targeting of the most aggressive subtype of pancreatic cancer. Cindy Leiton, Department of Pathology, Stony Brook Medicine, Stony Brook, NY, US.

A083. Three dimensional cellular drug screen identifies novel inhibitors of pancreatic acinar ductal metaplasia. Lais Da Silva, University of Florida, Gainesville, FL, USA.

A085. The beta-blocker propranolol as a supportive care option in a moue model of pancreatic cancer. Rubén Muñoz, TGen (Translational Genomic Research Inst.), Phoenix, AZ, USA



Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A086. A novel inhibitor that targets both p53-dependent apoptotic and autophagy pathways as a pancreatic cancer therapeutic. John Cashman, Human BioMolecular Research Institute & ChemRegen Inc., San Diego, CA, USA.

A087. Anemarrhena asphodeloides and its constituent timosaponin-AIII mitigate gemcitabine resistance in pancreatic cancer cells through increased deoxycytidine kinase expression. Catherine MarElia, University of South Florida, Tampa, FL, USA.

A088. Establishment of an Australian pancreatic cancer organoid biobank. Dannel Yeo, University of Melbourne, Melbourne, Australia.

A089. Genomic hallmarks of homologous repair deficiency predict response to targeted therapies in pancreatic cancer. Yifan Wang, McGill University, Montreal, QC, Canada.

A090. Identification of actionable variants for targeted therapy in COMPASS trial patient cohort. Amy Xin Wei Zhang, PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

A091. In vitro drug-response metrics of patient-derived cell lines that match drug effects on patient tumors. Jason Link, Oregon Health & Science University, Portland, OR, USA.

A092. Investigation of BRCAness in pancreatic cancer using patient-derived organoid models. Nicolas LECOMTE, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center (MSKCC), NEW YORK CITY, NY, USA.

A093. LIN28B in pancreas cancer: A driver of metastasis and drug resistance. Joseph Franses, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

A094. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Herve Tiriac, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

A095. Patient-derived organoids from endoscopic fine needle as a personalized diagnostic and prognostic tool in pancreatic ductal adenocarcinoma. Zahra Dantes, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria, Germany.

A096. PDAC Prognosis is Predicted by a Chromatin Accessibility Signature and Nuclear Localization of HNF1b and ZKSCAN1. Surajit Dhara, Norris Cotton Cancer Center, Lebanon, NH, USA.

A097. Plectin-1 as a novel therapeutic target in pancreatic cancer. Julien Dimastromatteo, University of Virginia - School of medicine - BME department, Charlottesville, VA, USA.



Pancreatic Cancer: Advances in Science and Clinical Care
September 21 - 24, 2018 | Boston, MA
AACR American Association for Cancer Research

Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A098. Retrospective Analysis of Patients using Olaparib (O) in Pancreatic Cancer (PC). Erkut Borazanci, HonorHealth/TGen, Scottsdale, AZ, USA.

A099. RNA expression of SERPINB7 is a poor predictor for the treatment of pancreatic cancer with gemcitabine. Daniela Bianconi, Medical University of Vienna, Vienna, Austria.

A100. Single sample RNA classifier for determining pancreatic ductal adenocarcinoma subtype. Richard Moffitt, Stony Brook University, Stony Brook, NY, USA.

A101. Targeting mitochondrial metabolism in PDAC via blockade of the APE1/Ref-1 signaling cascade: using single-cell RNA sequencing and proteomic analyses to identify novel targets for combination drug therapies. Fenil Shah, Indiana University School of Medicine, Indianapolis, IN, USA.

A102, PR06. The Know Your Tumor® initiative: Four years, a thousand patients, evidence of survival benefit, and the impact on patient lives. Lynn Matrisian, Pancreatic Cancer Action Network, Washington, DC, USA.

A103. Transcriptomic analysis of patient derived xenografts to investigate the role of the Vitamin D Receptor in pancreatic cancer. Sandra Roche, Dublin City University, Dublin, Ireland.

A104. Tumor and microenvironment transcriptomic features for the molecular stratification of pancreatic ductal adenocarcinoma. Remy Nicolle, Ligue contre le cancer, Paris, France.

A106. Aberrant Glycosylation Promotes Pancreatic Inflammation and Cancer. Dannielle Engle, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

A107. Association between progression of low risk IPMNs and diabetes mellitus. Christian Brooks, Columbia University Medical Center, New York, NY, USA.

A108. Endogenous insulin hypersecretion links diet-induced obesity to pancreatic cancer development in Ptf1a^{CreER};LSL-Kras^{G12D} mice. Anni Zhang, University of British Columbia, Vancouver, BC, Canada.

A109. Risk prediction model for pancreatic cancer in the general Japanese population. Yingsong Lin, Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.

A110. Daily physical activity monitoring predicts early development of pancreatic adenocarcinoma in mice.. Aaron Grossberg, Oregon Health & Science University, Portland, OR, USA.

A111. Alterations in hepatic carbohydrate metabolism impair the adaptive response to energy depletion in cancer.. Aaron Grossberg, Oregon Health & Science University, Portland, OR, USA.



Poster Session A

Saturday, Sept. 22, 2018
12:30–3 p.m.

A112. APOBEC3A catalyzes widespread chromosomal instability to drive an aggressive metastatic phenotype through engagement of cGAS/STING cytosolic DNA response in a novel genetic mouse model of pancreatic cancer. Andrew Rhim, UT MD Anderson Cancer Center, Houston, TX, USA.

A113. Successful organoid establishment from circulating tumor cells: utilizing brief leukapheresis to collect large numbers of CTCs from patients with pancreatic cancer. Andrew Rhim, UT MD Anderson Cancer Center, Houston, TX, USA.

A114. Investigation of the role of YAP in progression of KRAS mutated pancreatic lesions. Eric O'Neill, University of Oxford, Oxford, UK.

A115. Mutation of SMAD4 in pancreatic cancer results in an epigenetic switch in molecular subtypes via regulation of TET2 and Hydroxymethylation. Eric O'Neill, University of Oxford, Oxford, UK.